| Accession |
PRJCA010720 |
| Title |
Phase I clinical study of safety, tolerability, pharmacokinetics, and efficacy of SHR2554 in patients with relapsed/refractory mature lymphocytic tumors |
| Relevance |
Medical |
| Data types |
clinical data\Metabolic data\biomarker\image data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the safety and tolerability of SHR2554 monotherapy oral administration in patients with relapsed/refractory mature lymphocytic tumors to determine the high tolerated dose (MTD) and recommended dose for phase II clinical studies |
| Sample scope |
Multiisolate |
| Release date |
2022-07-23 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co. LTD
|
|
SHR-2554-I-101
|
|
|
|
| Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
| Submission date |
2022-07-22 |
